June 27, 2016 09:38 ET Examines Oculus Innovative Sciences' Financial Results and Turnaround Plan

REDONDO BEACH, CA--(Marketwired - Jun 27, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, takes a look at Oculus Innovative Sciences' (NASDAQ: OCLS) recently announced fourth quarter and fiscal year 2016 results, as well as the company's ambitious turnaround plan.

Oculus chalked out its plan based on four key initiatives, headlined by the main goal of penetrating the U.S. dermatology space as the core market. As part of reaching that goal, Oculus promised to bring its non-core markets to breakeven. Non-core markets include the company's sales in Latin America, Europe and Asia, as well as their animal health and advanced wound care businesses. "Non-core" sounds a little benign, given that these markets are still important growth drivers for Oculus; they just happen to be outside the domestic market that is the largest revenue opportunity. Oculus says that the breakeven goal for non-core markets will be met this quarter. A third promise was to diversify the portfolio to include products not built upon the company's proprietary Microcyn technology. Lastly, Oculus pledged to identify orphan drug or low-cost new drug application opportunities. 

To read the article, click on the following link or copy and paste the address in your browser:


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information